Bernd Seizinger Buys 60,000 Shares of Oncolytics Biotech (NASDAQ:ONCY) Stock

Oncolytics Biotech Inc. (NASDAQ:ONCY) Director Bernd Seizinger bought 60,000 shares of the firm’s stock in a transaction on Wednesday, February 11th. The stock was purchased at an average price of $0.83 per share, for a total transaction of $49,800.00. Following the completion of the acquisition, the director directly owned 526,991 shares in the company, valued at $437,402.53. The trade was a 12.85% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Oncolytics Biotech Stock Performance

ONCY stock opened at $0.83 on Friday. Oncolytics Biotech Inc. has a one year low of $0.33 and a one year high of $1.51. The firm has a market cap of $88.60 million, a PE ratio of -2.98 and a beta of 0.99. The firm’s 50 day moving average price is $0.98 and its 200-day moving average price is $1.07.

Oncolytics Biotech (NASDAQ:ONCY) last posted its earnings results on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. Equities research analysts predict that Oncolytics Biotech Inc. will post -0.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Oncolytics Biotech

Institutional investors have recently modified their holdings of the company. Scientech Research LLC acquired a new position in shares of Oncolytics Biotech during the third quarter worth $25,000. Seeds Investor LLC raised its stake in Oncolytics Biotech by 17.8% in the second quarter. Seeds Investor LLC now owns 223,767 shares of the company’s stock valued at $173,000 after buying an additional 33,826 shares in the last quarter. Ground Swell Capital LLC purchased a new stake in Oncolytics Biotech during the 4th quarter worth about $30,000. CIBC Private Wealth Group LLC purchased a new stake in Oncolytics Biotech during the 4th quarter worth about $44,000. Finally, Tocqueville Asset Management L.P. acquired a new position in shares of Oncolytics Biotech during the 4th quarter worth about $63,000. 6.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on ONCY shares. Wall Street Zen cut Oncolytics Biotech from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Zacks Research upgraded shares of Oncolytics Biotech from a “hold” rating to a “strong-buy” rating in a report on Friday, October 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Oncolytics Biotech in a research report on Monday, December 29th. Finally, HC Wainwright boosted their price target on shares of Oncolytics Biotech from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $6.25.

About Oncolytics Biotech

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.